0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Radioligand Therapy Drugs Market Research Report 2026
Published Date: 2026-01-10
|
Report Code: QYRE-Auto-18X20215
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Radioligand Therapy Drugs Market Research Report 2026
BUY CHAPTERS

Global Radioligand Therapy Drugs Market Research Report 2026

Code: QYRE-Auto-18X20215
Report
2026-01-10
Pages:125
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Radioligand Therapy Drugs Market Size

The global Radioligand Therapy Drugs market was valued at US$ 3155 million in 2025 and is anticipated to reach US$ 5346 million by 2032, at a CAGR of 8.0% from 2026 to 2032.

Radioligand Therapy Drugs Market

Radioligand Therapy Drugs Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Radioligand Therapy Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
In 2025, global Radioligand Therapy Drugs reached approximately 76.49 K Units, with an average global market price of around 41254 USD per Unit.
Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking “ligand” (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue.
Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active—including small or disseminated lesions—while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements—and in some settings competes with—established systemic therapies, shaping a long runway for growth without relying on hype.
Radioligand Therapy Drugs' upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer.
The production capacity of a single Radioligand Therapy Drugs production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs' gross profit margin ranges from 70% to 80%.
The North American market for Radioligand Therapy Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Radioligand Therapy Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Radioligand Therapy Drugs include Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, AstraZeneca, Eli Lilly, Convergent Therapeutics, Grand Pharmaceutical, Bivision Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Radioligand Therapy Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Radioligand Therapy Drugs. The Radioligand Therapy Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Radioligand Therapy Drugs market comprehensively. Regional market sizes by Type, by Application, by Targeted Ligands, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Radioligand Therapy Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Radioligand Therapy Drugs Market Report

Report Metric Details
Report Name Radioligand Therapy Drugs Market
Accounted market size in 2025 US$ 3155 in million
Forecasted market size in 2032 US$ 5346 million
CAGR 8.0%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Lutetium 177
  • Radium 223
  • Acetium 225
  • Others
Segment by Targeted Ligands
  • by Peptides
  • Small Molecules
  • Antibodies
  • Others
Segment by Radionuclides
  • β-emitters
  • α-emitters
  • Others
by Application
  • Prostate Cancer
  • Liver Cancer
  • Breast Cancer
  • Lung Cancer
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, AstraZeneca, Eli Lilly, Convergent Therapeutics, Grand Pharmaceutical, Bivision Pharmaceuticals, Jiangsu Hengrui
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Targeted Ligands, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Radioligand Therapy Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Radioligand Therapy Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Radioligand Therapy Drugs Market growing?

Ans: The Radioligand Therapy Drugs Market witnessing a CAGR of 8.0% during the forecast period 2026-2032.

What is the Radioligand Therapy Drugs Market size in 2032?

Ans: The Radioligand Therapy Drugs Market size in 2032 will be US$ 5346 million.

Who are the main players in the Radioligand Therapy Drugs Market report?

Ans: The main players in the Radioligand Therapy Drugs Market are Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, AstraZeneca, Eli Lilly, Convergent Therapeutics, Grand Pharmaceutical, Bivision Pharmaceuticals, Jiangsu Hengrui

What are the Application segmentation covered in the Radioligand Therapy Drugs Market report?

Ans: The Applications covered in the Radioligand Therapy Drugs Market report are Prostate Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Others

What are the Type segmentation covered in the Radioligand Therapy Drugs Market report?

Ans: The Types covered in the Radioligand Therapy Drugs Market report are Lutetium 177, Radium 223, Acetium 225, Others

1 Radioligand Therapy Drugs Market Overview
1.1 Product Definition
1.2 Radioligand Therapy Drugs by Type
1.2.1 Global Radioligand Therapy Drugs Market Value by Type: 2025 vs 2032
1.2.2 Lutetium 177
1.2.3 Radium 223
1.2.4 Acetium 225
1.2.5 Others
1.3 Radioligand Therapy Drugs by Targeted Ligands
1.3.1 Global Radioligand Therapy Drugs Market Value by Targeted Ligands: 2025 vs 2032
1.3.2 by Peptides
1.3.3 Small Molecules
1.3.4 Antibodies
1.3.5 Others
1.4 Radioligand Therapy Drugs by Radionuclides
1.4.1 Global Radioligand Therapy Drugs Market Value by Radionuclides: 2025 vs 2032
1.4.2 β-emitters
1.4.3 α-emitters
1.4.4 Others
1.5 Radioligand Therapy Drugs by Application
1.5.1 Global Radioligand Therapy Drugs Market Value by Application: 2025 vs 2032
1.5.2 Prostate Cancer
1.5.3 Liver Cancer
1.5.4 Breast Cancer
1.5.5 Lung Cancer
1.5.6 Others
1.6 Global Radioligand Therapy Drugs Market Size Estimates and Forecasts
1.6.1 Global Radioligand Therapy Drugs Revenue 2021–2032
1.6.2 Global Radioligand Therapy Drugs Sales 2021–2032
1.6.3 Global Radioligand Therapy Drugs Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Radioligand Therapy Drugs Market Competition by Manufacturers
2.1 Global Radioligand Therapy Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Radioligand Therapy Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Radioligand Therapy Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Radioligand Therapy Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Radioligand Therapy Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Radioligand Therapy Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Radioligand Therapy Drugs, Date of Entry into the Industry
2.8 Global Radioligand Therapy Drugs Market Competitive Situation and Trends
2.8.1 Global Radioligand Therapy Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Radioligand Therapy Drugs Players Market Share by Revenue
2.8.3 Global Radioligand Therapy Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Radioligand Therapy Drugs Market Scenario by Region
3.1 Global Radioligand Therapy Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Radioligand Therapy Drugs Sales by Region: 2021–2032
3.2.1 Global Radioligand Therapy Drugs Sales by Region: 2021–2026
3.2.2 Global Radioligand Therapy Drugs Sales by Region: 2027–2032
3.3 Global Radioligand Therapy Drugs Revenue by Region: 2021–2032
3.3.1 Global Radioligand Therapy Drugs Revenue by Region: 2021–2026
3.3.2 Global Radioligand Therapy Drugs Revenue by Region: 2027–2032
3.4 North America Radioligand Therapy Drugs Market Facts & Figures by Country
3.4.1 North America Radioligand Therapy Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Radioligand Therapy Drugs Sales by Country (2021–2032)
3.4.3 North America Radioligand Therapy Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Radioligand Therapy Drugs Market Facts & Figures by Country
3.5.1 Europe Radioligand Therapy Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Radioligand Therapy Drugs Sales by Country (2021–2032)
3.5.3 Europe Radioligand Therapy Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Radioligand Therapy Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Radioligand Therapy Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Radioligand Therapy Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Radioligand Therapy Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Radioligand Therapy Drugs Market Facts & Figures by Country
3.7.1 Latin America Radioligand Therapy Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Radioligand Therapy Drugs Sales by Country (2021–2032)
3.7.3 Latin America Radioligand Therapy Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Radioligand Therapy Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Radioligand Therapy Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Radioligand Therapy Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Radioligand Therapy Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Radioligand Therapy Drugs Sales by Type (2021–2032)
4.1.1 Global Radioligand Therapy Drugs Sales by Type (2021–2026)
4.1.2 Global Radioligand Therapy Drugs Sales by Type (2027–2032)
4.1.3 Global Radioligand Therapy Drugs Sales Market Share by Type (2021–2032)
4.2 Global Radioligand Therapy Drugs Revenue by Type (2021–2032)
4.2.1 Global Radioligand Therapy Drugs Revenue by Type (2021–2026)
4.2.2 Global Radioligand Therapy Drugs Revenue by Type (2027–2032)
4.2.3 Global Radioligand Therapy Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Radioligand Therapy Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Radioligand Therapy Drugs Sales by Application (2021–2032)
5.1.1 Global Radioligand Therapy Drugs Sales by Application (2021–2026)
5.1.2 Global Radioligand Therapy Drugs Sales by Application (2027–2032)
5.1.3 Global Radioligand Therapy Drugs Sales Market Share by Application (2021–2032)
5.2 Global Radioligand Therapy Drugs Revenue by Application (2021–2032)
5.2.1 Global Radioligand Therapy Drugs Revenue by Application (2021–2026)
5.2.2 Global Radioligand Therapy Drugs Revenue by Application (2027–2032)
5.2.3 Global Radioligand Therapy Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Radioligand Therapy Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Radioligand Therapy Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Company Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Bayer Radioligand Therapy Drugs Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Progenics (Lantheus)
6.3.1 Progenics (Lantheus) Company Information
6.3.2 Progenics (Lantheus) Description and Business Overview
6.3.3 Progenics (Lantheus) Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Progenics (Lantheus) Radioligand Therapy Drugs Product Portfolio
6.3.5 Progenics (Lantheus) Recent Developments/Updates
6.4 Acrotech Biopharma Inc
6.4.1 Acrotech Biopharma Inc Company Information
6.4.2 Acrotech Biopharma Inc Description and Business Overview
6.4.3 Acrotech Biopharma Inc Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Acrotech Biopharma Inc Radioligand Therapy Drugs Product Portfolio
6.4.5 Acrotech Biopharma Inc Recent Developments/Updates
6.5 BMS
6.5.1 BMS Company Information
6.5.2 BMS Description and Business Overview
6.5.3 BMS Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 BMS Radioligand Therapy Drugs Product Portfolio
6.5.5 BMS Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Company Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 AstraZeneca Radioligand Therapy Drugs Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Eli Lilly
6.7.1 Eli Lilly Company Information
6.7.2 Eli Lilly Description and Business Overview
6.7.3 Eli Lilly Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Eli Lilly Radioligand Therapy Drugs Product Portfolio
6.7.5 Eli Lilly Recent Developments/Updates
6.8 Convergent Therapeutics
6.8.1 Convergent Therapeutics Company Information
6.8.2 Convergent Therapeutics Description and Business Overview
6.8.3 Convergent Therapeutics Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Convergent Therapeutics Radioligand Therapy Drugs Product Portfolio
6.8.5 Convergent Therapeutics Recent Developments/Updates
6.9 Grand Pharmaceutical
6.9.1 Grand Pharmaceutical Company Information
6.9.2 Grand Pharmaceutical Description and Business Overview
6.9.3 Grand Pharmaceutical Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Grand Pharmaceutical Radioligand Therapy Drugs Product Portfolio
6.9.5 Grand Pharmaceutical Recent Developments/Updates
6.10 Bivision Pharmaceuticals
6.10.1 Bivision Pharmaceuticals Company Information
6.10.2 Bivision Pharmaceuticals Description and Business Overview
6.10.3 Bivision Pharmaceuticals Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bivision Pharmaceuticals Radioligand Therapy Drugs Product Portfolio
6.10.5 Bivision Pharmaceuticals Recent Developments/Updates
6.11 Jiangsu Hengrui
6.11.1 Jiangsu Hengrui Company Information
6.11.2 Jiangsu Hengrui Description and Business Overview
6.11.3 Jiangsu Hengrui Radioligand Therapy Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Jiangsu Hengrui Radioligand Therapy Drugs Product Portfolio
6.11.5 Jiangsu Hengrui Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Radioligand Therapy Drugs Industry Chain Analysis
7.2 Radioligand Therapy Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Radioligand Therapy Drugs Production Mode & Process Analysis
7.4 Radioligand Therapy Drugs Sales and Marketing
7.4.1 Radioligand Therapy Drugs Sales Channels
7.4.2 Radioligand Therapy Drugs Distributors
7.5 Radioligand Therapy Drugs Customer Analysis
8 Radioligand Therapy Drugs Market Dynamics
8.1 Radioligand Therapy Drugs Industry Trends
8.2 Radioligand Therapy Drugs Market Drivers
8.3 Radioligand Therapy Drugs Market Challenges
8.4 Radioligand Therapy Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Radioligand Therapy Drugs Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Radioligand Therapy Drugs Market Value by Targeted Ligands (US$ Million), 2025 vs 2032
 Table 3. Global Radioligand Therapy Drugs Market Value by Radionuclides (US$ Million), 2025 vs 2032
 Table 4. Global Radioligand Therapy Drugs Market Value by Application (US$ Million), 2025 vs 2032
 Table 5. Global Radioligand Therapy Drugs Market Competitive Situation by Manufacturers in 2025
 Table 6. Global Radioligand Therapy Drugs Sales (K Units) of Key Manufacturers (2021–2026)
 Table 7. Global Radioligand Therapy Drugs Sales Market Share by Manufacturers (2021–2026)
 Table 8. Global Radioligand Therapy Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 9. Global Radioligand Therapy Drugs Revenue Share by Manufacturers (2021–2026)
 Table 10. Global Market Radioligand Therapy Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 11. Global Key Players of Radioligand Therapy Drugs, Industry Ranking, 2023 vs 2024 vs 2025
 Table 12. Global Key Manufacturers of Radioligand Therapy Drugs, Manufacturing Sites and Headquarters
 Table 13. Global Key Manufacturers of Radioligand Therapy Drugs, Product Types and Applications
 Table 14. Global Key Manufacturers of Radioligand Therapy Drugs, Date of Entry into the Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Radioligand Therapy Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Radioligand Therapy Drugs Revenue, 2025
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Radioligand Therapy Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 19. Global Radioligand Therapy Drugs Sales by Region (K Units), 2021–2026
 Table 20. Global Radioligand Therapy Drugs Sales Market Share by Region (2021–2026)
 Table 21. Global Radioligand Therapy Drugs Sales by Region (K Units), 2027–2032
 Table 22. Global Radioligand Therapy Drugs Sales Market Share by Region (2027–2032)
 Table 23. Global Radioligand Therapy Drugs Revenue by Region (US$ Million), 2021–2026
 Table 24. Global Radioligand Therapy Drugs Revenue Market Share by Region (2021–2026)
 Table 25. Global Radioligand Therapy Drugs Revenue by Region (US$ Million), 2027–2032
 Table 26. Global Radioligand Therapy Drugs Revenue Market Share by Region (2027–2032)
 Table 27. North America Radioligand Therapy Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 28. North America Radioligand Therapy Drugs Sales by Country (K Units), 2021–2026
 Table 29. North America Radioligand Therapy Drugs Sales by Country (K Units), 2027–2032
 Table 30. North America Radioligand Therapy Drugs Revenue by Country (US$ Million), 2021–2026
 Table 31. North America Radioligand Therapy Drugs Revenue by Country (US$ Million), 2027–2032
 Table 32. Europe Radioligand Therapy Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 33. Europe Radioligand Therapy Drugs Sales by Country (K Units), 2021–2026
 Table 34. Europe Radioligand Therapy Drugs Sales by Country (K Units), 2027–2032
 Table 35. Europe Radioligand Therapy Drugs Revenue by Country (US$ Million), 2021–2026
 Table 36. Europe Radioligand Therapy Drugs Revenue by Country (US$ Million), 2027–2032
 Table 37. Asia Pacific Radioligand Therapy Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 38. Asia Pacific Radioligand Therapy Drugs Sales by Region (K Units), 2021–2026
 Table 39. Asia Pacific Radioligand Therapy Drugs Sales by Region (K Units), 2027–2032
 Table 40. Asia Pacific Radioligand Therapy Drugs Revenue by Region (US$ Million), 2021–2026
 Table 41. Asia Pacific Radioligand Therapy Drugs Revenue by Region (US$ Million), 2027–2032
 Table 42. Latin America Radioligand Therapy Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 43. Latin America Radioligand Therapy Drugs Sales by Country (K Units), 2021–2026
 Table 44. Latin America Radioligand Therapy Drugs Sales by Country (K Units), 2027–2032
 Table 45. Latin America Radioligand Therapy Drugs Revenue by Country (US$ Million), 2021–2026
 Table 46. Latin America Radioligand Therapy Drugs Revenue by Country (US$ Million), 2027–2032
 Table 47. Middle East and Africa Radioligand Therapy Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 48. Middle East and Africa Radioligand Therapy Drugs Sales by Country (K Units), 2021–2026
 Table 49. Middle East and Africa Radioligand Therapy Drugs Sales by Country (K Units), 2027–2032
 Table 50. Middle East and Africa Radioligand Therapy Drugs Revenue by Country (US$ Million), 2021–2026
 Table 51. Middle East and Africa Radioligand Therapy Drugs Revenue by Country (US$ Million), 2027–2032
 Table 52. Global Radioligand Therapy Drugs Sales (K Units) by Type (2021–2026)
 Table 53. Global Radioligand Therapy Drugs Sales (K Units) by Type (2027–2032)
 Table 54. Global Radioligand Therapy Drugs Sales Market Share by Type (2021–2026)
 Table 55. Global Radioligand Therapy Drugs Sales Market Share by Type (2027–2032)
 Table 56. Global Radioligand Therapy Drugs Revenue (US$ Million) by Type (2021–2026)
 Table 57. Global Radioligand Therapy Drugs Revenue (US$ Million) by Type (2027–2032)
 Table 58. Global Radioligand Therapy Drugs Revenue Market Share by Type (2021–2026)
 Table 59. Global Radioligand Therapy Drugs Revenue Market Share by Type (2027–2032)
 Table 60. Global Radioligand Therapy Drugs Price (US$/Unit) by Type (2021–2026)
 Table 61. Global Radioligand Therapy Drugs Price (US$/Unit) by Type (2027–2032)
 Table 62. Global Radioligand Therapy Drugs Sales (K Units) by Application (2021–2026)
 Table 63. Global Radioligand Therapy Drugs Sales (K Units) by Application (2027–2032)
 Table 64. Global Radioligand Therapy Drugs Sales Market Share by Application (2021–2026)
 Table 65. Global Radioligand Therapy Drugs Sales Market Share by Application (2027–2032)
 Table 66. Global Radioligand Therapy Drugs Revenue (US$ Million) by Application (2021–2026)
 Table 67. Global Radioligand Therapy Drugs Revenue (US$ Million) by Application (2027–2032)
 Table 68. Global Radioligand Therapy Drugs Revenue Market Share by Application (2021–2026)
 Table 69. Global Radioligand Therapy Drugs Revenue Market Share by Application (2027–2032)
 Table 70. Global Radioligand Therapy Drugs Price (US$/Unit) by Application (2021–2026)
 Table 71. Global Radioligand Therapy Drugs Price (US$/Unit) by Application (2027–2032)
 Table 72. Novartis Company Information
 Table 73. Novartis Description and Business Overview
 Table 74. Novartis Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 75. Novartis Radioligand Therapy Drugs Product
 Table 76. Novartis Recent Developments/Updates
 Table 77. Bayer Company Information
 Table 78. Bayer Description and Business Overview
 Table 79. Bayer Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 80. Bayer Radioligand Therapy Drugs Product
 Table 81. Bayer Recent Developments/Updates
 Table 82. Progenics (Lantheus) Company Information
 Table 83. Progenics (Lantheus) Description and Business Overview
 Table 84. Progenics (Lantheus) Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 85. Progenics (Lantheus) Radioligand Therapy Drugs Product
 Table 86. Progenics (Lantheus) Recent Developments/Updates
 Table 87. Acrotech Biopharma Inc Company Information
 Table 88. Acrotech Biopharma Inc Description and Business Overview
 Table 89. Acrotech Biopharma Inc Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 90. Acrotech Biopharma Inc Radioligand Therapy Drugs Product
 Table 91. Acrotech Biopharma Inc Recent Developments/Updates
 Table 92. BMS Company Information
 Table 93. BMS Description and Business Overview
 Table 94. BMS Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 95. BMS Radioligand Therapy Drugs Product
 Table 96. BMS Recent Developments/Updates
 Table 97. AstraZeneca Company Information
 Table 98. AstraZeneca Description and Business Overview
 Table 99. AstraZeneca Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 100. AstraZeneca Radioligand Therapy Drugs Product
 Table 101. AstraZeneca Recent Developments/Updates
 Table 102. Eli Lilly Company Information
 Table 103. Eli Lilly Description and Business Overview
 Table 104. Eli Lilly Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 105. Eli Lilly Radioligand Therapy Drugs Product
 Table 106. Eli Lilly Recent Developments/Updates
 Table 107. Convergent Therapeutics Company Information
 Table 108. Convergent Therapeutics Description and Business Overview
 Table 109. Convergent Therapeutics Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 110. Convergent Therapeutics Radioligand Therapy Drugs Product
 Table 111. Convergent Therapeutics Recent Developments/Updates
 Table 112. Grand Pharmaceutical Company Information
 Table 113. Grand Pharmaceutical Description and Business Overview
 Table 114. Grand Pharmaceutical Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 115. Grand Pharmaceutical Radioligand Therapy Drugs Product
 Table 116. Grand Pharmaceutical Recent Developments/Updates
 Table 117. Bivision Pharmaceuticals Company Information
 Table 118. Bivision Pharmaceuticals Description and Business Overview
 Table 119. Bivision Pharmaceuticals Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 120. Bivision Pharmaceuticals Radioligand Therapy Drugs Product
 Table 121. Bivision Pharmaceuticals Recent Developments/Updates
 Table 122. Jiangsu Hengrui Company Information
 Table 123. Jiangsu Hengrui Description and Business Overview
 Table 124. Jiangsu Hengrui Radioligand Therapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 125. Jiangsu Hengrui Radioligand Therapy Drugs Product
 Table 126. Jiangsu Hengrui Recent Developments/Updates
 Table 127. Key Raw Materials Lists
 Table 128. Raw Materials Key Suppliers Lists
 Table 129. Radioligand Therapy Drugs Distributors List
 Table 130. Radioligand Therapy Drugs Customers List
 Table 131. Radioligand Therapy Drugs Market Trends
 Table 132. Radioligand Therapy Drugs Market Drivers
 Table 133. Radioligand Therapy Drugs Market Challenges
 Table 134. Radioligand Therapy Drugs Market Restraints
 Table 135. Research Programs/Design for This Report
 Table 136. Key Data Information from Secondary Sources
 Table 137. Key Data Information from Primary Sources
 Table 138. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Radioligand Therapy Drugs
 Figure 2. Global Radioligand Therapy Drugs Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Radioligand Therapy Drugs Market Share by Type: 2025 & 2032
 Figure 4. Lutetium 177 Product Picture
 Figure 5. Radium 223 Product Picture
 Figure 6. Acetium 225 Product Picture
 Figure 7. Others Product Picture
 Figure 8. Global Radioligand Therapy Drugs Market Value by Targeted Ligands (US$ Million), 2021–2032
 Figure 9. Global Radioligand Therapy Drugs Market Share by Targeted Ligands: 2025 vs 2032
 Figure 10. by Peptides Product Picture
 Figure 11. Small Molecules Product Picture
 Figure 12. Antibodies Product Picture
 Figure 13. Others Product Picture
 Figure 14. Global Radioligand Therapy Drugs Market Value by Radionuclides (US$ Million), 2021–2032
 Figure 15. Global Radioligand Therapy Drugs Market Share by Radionuclides: 2025 vs 2032
 Figure 16. β-emitters Product Picture
 Figure 17. α-emitters Product Picture
 Figure 18. Others Product Picture
 Figure 19. Global Radioligand Therapy Drugs Market Value by Application (US$ Million), 2021–2032
 Figure 20. Global Radioligand Therapy Drugs Market Share by Application: 2025 & 2032
 Figure 21. Prostate Cancer
 Figure 22. Liver Cancer
 Figure 23. Breast Cancer
 Figure 24. Lung Cancer
 Figure 25. Others
 Figure 26. Global Radioligand Therapy Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 27. Global Radioligand Therapy Drugs Market Size (US$ Million), 2021–2032
 Figure 28. Global Radioligand Therapy Drugs Sales (K Units), 2021–2032
 Figure 29. Global Radioligand Therapy Drugs Average Price (US$/Unit), 2021–2032
 Figure 30. Radioligand Therapy Drugs Report Years Considered
 Figure 31. Radioligand Therapy Drugs Sales Share by Manufacturers in 2025
 Figure 32. Global Radioligand Therapy Drugs Revenue Share by Manufacturers in 2025
 Figure 33. Top 5 and Top 10 Global Radioligand Therapy Drugs Players: Market Share by Revenue in Radioligand Therapy Drugs in 2025
 Figure 34. Radioligand Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 35. Global Radioligand Therapy Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 36. North America Radioligand Therapy Drugs Sales Market Share by Country (2021–2032)
 Figure 37. North America Radioligand Therapy Drugs Revenue Market Share by Country (2021–2032)
 Figure 38. United States Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. Canada Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Europe Radioligand Therapy Drugs Sales Market Share by Country (2021–2032)
 Figure 41. Europe Radioligand Therapy Drugs Revenue Market Share by Country (2021–2032)
 Figure 42. Germany Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. France Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. U.K. Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Italy Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Russia Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Asia Pacific Radioligand Therapy Drugs Sales Market Share by Region (2021–2032)
 Figure 48. Asia Pacific Radioligand Therapy Drugs Revenue Market Share by Region (2021–2032)
 Figure 49. China Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Japan Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. South Korea Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. India Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Australia Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. China Taiwan Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Southeast Asia Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Latin America Radioligand Therapy Drugs Sales Market Share by Country (2021–2032)
 Figure 57. Latin America Radioligand Therapy Drugs Revenue Market Share by Country (2021–2032)
 Figure 58. Mexico Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 59. Brazil Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 60. Argentina Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 61. Colombia Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 62. Middle East and Africa Radioligand Therapy Drugs Sales Market Share by Country (2021–2032)
 Figure 63. Middle East and Africa Radioligand Therapy Drugs Revenue Market Share by Country (2021–2032)
 Figure 64. Turkey Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 65. Saudi Arabia Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 66. UAE Radioligand Therapy Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 67. Global Sales Market Share of Radioligand Therapy Drugs by Type (2021–2032)
 Figure 68. Global Revenue Market Share of Radioligand Therapy Drugs by Type (2021–2032)
 Figure 69. Global Radioligand Therapy Drugs Price (US$/Unit) by Type (2021–2032)
 Figure 70. Global Sales Market Share of Radioligand Therapy Drugs by Application (2021–2032)
 Figure 71. Global Revenue Market Share of Radioligand Therapy Drugs by Application (2021–2032)
 Figure 72. Global Radioligand Therapy Drugs Price (US$/Unit) by Application (2021–2032)
 Figure 73. Radioligand Therapy Drugs Value Chain
 Figure 74. Channels of Distribution (Direct Vs Distribution)
 Figure 75. Bottom-up and Top-down Approaches for This Report
 Figure 76. Data Triangulation
 Figure 77. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String

SIMILAR REPORTS